Renal Business Today

Abbott

Abbott to Separate into Two Companies

ABBOTT PARK, Ill.—Abbott announced its plans to separate into two publicly traded companies, one in diversified medical products and the other in research-based pharmaceuticals. ...More
October 20, 2011
Posted in News, Business
FDA Approves Abbott Renal Stent System

ABBOTT PARK, Ill.—The U.S. Food and Drug Administration (FDA) has approved Abbott’s RX Herculink Elite Renal Stent System for the treatment of renal artery stenosis in patients with uncontrolled hypertension. ...More
August 11, 2011
Posted in News, Clinical & Pharma, Government & Regulation
Drug Improves Kidney Function in Diabetics

PRAGUE—Type 2 diabetics receiving the drug bardoxolone methyl experiences sustained improvement in their kidney function over the course of a 52-week treatment period, according to a phase 2 study published online June 24 in the New England Journal of Medicine. ...More
June 24, 2011
Posted in News, Clinical & Pharma
Drug May Slow Kidney Disease in Diabetic Nephropathy Patients

SALT LAKE CITY—The drug atrasentan could reduce the progression of kidney disease related to diabetic nephropathy, which is a common complication of diabetes that can also damage nerves and injure blood vessels, the eyes, heart, and other organs, according to a study ...More
March 10, 2011
Posted in News, Clinical & Pharma
FDA Recalls Millions of Diabetes Test Strips

The U.S. Food and Drug Administration is working with Abbott Diabetes Care to recall 359 lots of glucose test strips because they may falsely give low blood glucose results. ...More
December 28, 2010
Posted in Blog, Government & Regulation
Pharma Companies Pay $421.2M to Settle False Claims Act Cases

WASHINGTON—Abbott Laboratories Inc., B. Braun Medical Inc. and Roxane Laboratories Inc., though Boehringer Ingelheim Roxane Inc. and affiliated entities, have agreed to pay $421 million to settle False Claims Act allegations, the U.S. Justice Department announced on Dec. 7. ...More
December 8, 2010
Posted in News, Business, Government & Regulation
Abbott, Reata Pharma to Develop Bardoxolone Methyl for CKD

ABBOTT PARK, Ill.—Abbott and Reata Pharmaceuticals announced that they have entered into a collaboration agreement to develop and commercialize bardoxolone methyl (bardoxolone), which is currently in late Phase 2 trials for the treatment of chronic kidney disease (CKD). ...More
September 23, 2010
Posted in News, Business
FDA to Review Abbott's Kidney Test

The FDA has accepted for review Abbott Laboratories’ diagnostic test that detects an early biomarker which identifies patients at risk for acute kidney injury. ...More
April 6, 2010
Posted in News, Business, Clinical & Pharma, Practice Management
Medical Directors Concerned About Bundle, Patient Outcomes

EXTON, Pa.—Medical directors report a significantly higher awareness of the dialysis bundle and have become decidedly more negative about the impact to patient outcomes, according to new results released March 24 by BioTrendsResearch Group. ...More
March 24, 2010
Posted in News, Business, Clinical & Pharma, Government & Regulation, Practice Management
Report: Product Shifts in Renal Anemia, Bone, Mineral Metabolism Markets

EXTON, Pa.—Product shifts are occurring in the renal anemia and bone and mineral metabolism markets, according to BioTrends Research Group’s most recent TreatmentTrends®: US Nephrology Report syndicated report based on online survey results of more than 200 ...More
April 28, 2009
Posted in News, Business, Clinical & Pharma, Practice Management